Alzheimer therapy passes another important test
Drug candidate PRI-002 has successfully completed Phase I of clinical research
14-May-2019 -
The Alzheimer drug candidate PRI-002 developed at Forschungszentrum Jülich has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will ...
Alzheimer's disease
drug candidates